Asset resuscitation fails to resuscitate Mereo
Mereo claims another success with a big pharma castoff, but its win in alpha 1-antitrypsin deficiency is questionable.
Bristol needs to get fresh
Move over Amgen – Bristol Myers Squibb now looks like the big biopharma group most in need of revitalisation.
Protagonist “delighted” with trial failure
Development of the ulcerative colitis project PN-943 continues.
First-quarter biotech risers work hard for the win
Amid a difficult start to the year for the drug development sector, Abbvie, Bayer, Ipsen and Lantheus stand out as stock market gainers.
Protagonist seeks an Ideal readout
A mid-stage hit with its ulcerative colitis project could see the company on course for blockbuster sales.
Biotech catalysts on the horizon
The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
